»
Biochemical Pharmacology
 
 

Biochemical Pharmacology

 
 

Journal

 4.650(2013)

4.529

Editor-in-Chief::S.J. Enna

Show

00062952

93-98

24

Go to Journal Website

eJournal

Subscription Details

ScienceDirect Subscription

  • Access for 5 users
  • Access to 4 years of archives

USD 11,285.60

Print Journal

Subscription Details

Estimated Delivery Time


In Stock

USD 11,286.00
Buying for Institutions
Terms & Conditions

Additional Subscription Help

 
 
 

Aims & Scope

Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.

The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.

All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.

While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.

Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study.

The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature.

Original research submissions must contain:

  • A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulators of receptors, enzymes and signaling pathways.
  • Justification must also be provided for the selection of the statistical tests employed as they relate to the experimental design.
  • It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series.
  • Manuscripts that fail to meet these criteria will be subject to rejection without peer-review.

US National Institutes of Health (NIH) voluntary posting ("Public Access") policy
Biochemical Pharmacology and Elsevier facilitate the author's response to the NIH Public Access Policy.

Please bookmark this URL: http://www.elsevier.com/locate/biochempharm

Benefits to authors
We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .

Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: click here

Audience

Pharmacologists, Biochemists, Toxicologists, Neuroscientists, Molecular and Cellular Biologists.

Abstracting and Indexing

BIOSIS, Chemical Abstracts, Current Contents/ASCA, Current Contents/BIOMED Database, Current Contents/Life Sciences, Current Contents/SciSearch Database, Current Contents/Science Citation Index, EMBASE, Elsevier BIOBASE, MEDLINE®, PASCAL/CNRS, Reference Update, Scopus
Editor-in-Chief: S.J. Enna University of Kansas Medical Center, Kansas City, KS, USA, Editors: J.G. Piette Université de Liège, Liège, Belgium, K. Mullane Profectus Pharma Consulting, Inc., San Jose, CA, USA, Commentary Editor: M. Williams Northwestern University, lake Forest, IL, USA, Editorial Office: Biochemical Pharmacology University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 4016, Kansas City, KS 66160, USA, Fax: +1-913-588-7373, Managing Editor: L. LeCount , Editorial Coordinator: C. Martin , Editorial Advisory Board , Antibiotics and Chemotherapeutics B.B. Aggarwal University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA, R. Alfieri University of Parma, Parma, Italy, C. Bailly Institut de Recherche Pierre Fabre, Toulouse, France, E. A. Bey West Virginia University, Morgantown, WV, USA, S. Ceruti Università degli Studi di Milano, Milano, Italy, B.S. Cummings University of Georgia, Athens, GA, USA, M. Davies University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, E. De Clercq KU Leuven, Leuven, Belgium, M. Diederich Cancer and Blood Disease Research Foundation, Luxembourg, Luxembourg, J.-D. Docquier Università degli Studi di Siena, Siena, Italy, M. Galleni Université de Liège, Liège, Belgium, HP. Gerber Pfizer Biotherapeutics, Pearl River, NY, USA, R. Ghosh University of Texas Health Science Center at San Antonio , San Antonio, TX, USA, C. Giardina University of Connecticut, Storrs, CT, USA, O. Handa Kyoto Prefectural University of Medicine, Kyoto, Japan, K. Kashfi City University of New York (CUNY), New York, NY, USA, F.A.E. Kruyt Universitair Medisch Centrum Groningen, Groningen, Netherlands, I. Marzo Universidad de Zaragoza, Zaragoza, Spain, C. Michiels Université de Namur, Namur, Belgium, J. Neyts KU Leuven, Leuven, Belgium, S. Nock Cephalon, Inc., Redwood City, CA, USA, B.A. Ruggeri Cephalon, Inc., West Chester, PA, USA, G.L. Russo Consiglio Nazionale delle Ricerche, Avellino, Italy, K.S.M. Smalley H. Lee Moffitt Cancer Center, Tampa, FL, USA, F. Takahashi-Yanaga Kyushu University, Fukuoka, Japan, B.A. Teicher National Cancer Institute, Rockville, MD, USA, K.D. Tew Medical University of South Carolina, Charleston, SC, USA, G. Viola Università degli Studi di Padova, Padova, Italy, J. Wang Shanghai Medicilon, Inc., Shanghai, China, F. Zunino National Institute for the Study and Cure of Tumors, Milan, Italy, Cardiovascular P. Anversa Brigham and Women's Hospital, Boston, MA, USA, M.R. Bennett University of Cambridge, Cambridge, UK, Y.-H. Feng Uniformed Services University of Health Sciences, Bethesda, MD, USA, D. Fitzgerald University College Dublin, Belfield, Ireland, B.M. Frey-von Matt Universitätspoliklinik Bern, Bern, Switzerland, R.A. Khalil Harvard Medical School, W. Roxbury, MA, USA, D. Newby University of Edinburgh, Edinburgh, UK, F.G. Spinale University of South Carolina, Columbia, SC, USA, B. Staels Institut Pasteur, Lille, France, R.J. Winquist Vertex Pharmaceuticals Inc, Cambridge, MA, USA, Metabolic Disorders and Endocrinology N. Chattopadhyay Central Drug Research Institute, Lucknow, Uttar Pradesh, India, I. de Lannoy NoAb BioDiscoveries Inc., Mississauga, ON, Canada, Y. Kanai Osaka University, Suita-Shi, Japan, A. Kowluru Wayne State University, Detroit, MI, USA, J. Pierre INSERM U749, Villejuif, France, M.E. Poirot Institut Claudius Regaud, Toulouse, France, C.D. Sutherland University of Dundee, Dundee, UK, H. Yamazaki Showa Pharmaceutical University, Tokyo, Japan, Inflammation and Immunopharmacology M.J. Alcaraz Universitat de València, Valencia, Spain, R. Beyaert Universiteit Gent, Gent (Zwijnaarde), Belgium, A. Bowie Trinity College, Dublin, Ireland, M. Burczynski Bristol-Myers Squibb Co., Pennington, NJ, USA, F. D'Acquisto William Harvey Research Institute, London, UK, J. El Benna INSERM, Paris, France, M.P. Fink University of California at Los Angeles (UCLA), Los Angeles, CA, USA, K.B. Glaser Abbott Laboratories, Abbott Park, IL, USA, J.P. Hardwick Northeastern Ohio University College of Medicine, Rootstown, OH, USA, J.-H. Lai Chang Gung Memorial Hospital, Taiwan, E. Lavelle Trinity College Dublin, Dublin 2, Ireland, O. Lèo Université Libre de Bruxelles, Gosselies, Belgium, K. McCoy Virginia Commonwealth University, Richmond, VA, USA, A. Miller Carmel Med
 
 
 
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us

Author Services

Prepare your Article for submission
Translation Services
English Language Editing
Illustrations

Celebrate your publication success
Article Offprints, Journal Issues, Article/Cover Posters, Create Your Own Book

Additional Services
Mobile Apps,Special Content Offerings,and more...